Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

15.28
+0.63004.30%
Volume:483.76K
Turnover:7.29M
Market Cap:1.81B
PE:-13.20
High:15.40
Open:14.75
Low:14.74
Close:14.65
Loading ...

Arcutis Biotherapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
28 Feb

Arcutis Biotherapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
27 Feb

BUZZ-U.S. STOCKS ON THE MOVE-Cheesecake Factory, SiriusPoint, Arcutis Biosciences

Reuters
·
27 Feb

BUZZ-Arcutis Biotherapeutics rises on strong sales of skin disease drug

Reuters
·
26 Feb

Strong Buy Rating for Arcutis Biotherapeutics Driven by Zoryve’s Growth and Market Expansion

TIPRANKS
·
26 Feb

Arcutis Biotherapeutics Shares up 5.3% After Narrower Q4 Loss

THOMSON REUTERS
·
26 Feb

Arcutis Biotherapeutics Says FDA Accepts Supplemental New Drug Application for Zoryve Cream

MT Newswires Live
·
26 Feb

Arcutis Biotherapeutics Inc - FDA Sets Pdufa Target Action Date of Oct 13, 2025

THOMSON REUTERS
·
26 Feb

U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ Zoryve® (Roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 With Mild to Moderate Atopic Dermatitis

THOMSON REUTERS
·
26 Feb

Arcutis Biotherapeutics Inc : Mizuho Raises Target Price to $21 From $20

THOMSON REUTERS
·
26 Feb

Arcutis Biotherapeutics Price Target Maintained With a $20.00/Share by Needham

Dow Jones
·
26 Feb

Stock Track | Arcutis Biotherapeutics (ARQT) Soars 9.18% Pre-Market on Stellar Q4 Results, Driven by Robust ZORYVE Sales

Stock Track
·
26 Feb

Arcutis Biotherapeutics Q4 Loss Narrows, Revenue Rises

MT Newswires Live
·
26 Feb

Arcutis Biotherapeutics Inc (ARQT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com
·
26 Feb

Arcutis Biotherapeutics Reports Strong 2024 Revenue Growth

TIPRANKS
·
26 Feb

Strong Market Position and Growth Potential for Arcutis Biotherapeutics Driven by Zoryve’s Success and Strategic Initiatives

TIPRANKS
·
26 Feb

Stock Track | Arcutis Biotherapeutics (ARQT) Soars 9% on Stellar Q4 Results Driven by ZORYVE Sales

Stock Track
·
26 Feb

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
26 Feb

Arcutis Biotherapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Feb

Stock Track | Arcutis Biotherapeutics (ARQT) Soars 8.36% After Hours on Robust Q4 Earnings Beat and ZORYVE Sales Growth

Stock Track
·
26 Feb